Celltrion Signs Supply Contract Worth 41 Billion KRW for Remsima IV and Others
[Asia Economy Reporter Oh Hyung-gil] Celltrion announced on the 7th that it has signed a supply contract worth 41 billion KRW for biosimilar antibody drugs (Remsima IV, Remsima SC) with its affiliate Celltrion Healthcare.
Hot Picks Today
After Topping 8,000 Instead of Hitting 10,000... KOSPI Plunges—When Will It Rebound?
- "Samsung and Hynix Were Once for the Underachievers"... Hyundai Motor Employee's Lament
- [Breaking] Court Rules Against Samsung Electronics Union...1 Billion Won per Day Penalty for Exceeding Strike Scope
- Six Economic Organizations Urge Withdrawal of Samsung Electronics Strike Plan...Warn of National Loss of Opportunity
- "That? It's Already Stashed" Nightlife Scene Crosses the Line [ChwiYak Nation] ③
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
